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Abstract
The conflicting results of recent pre-exposure prophylaxis (PrEP) trials utilizing tenofovir (TFV) to prevent HIV infection in
women led us to evaluate the accumulation of intracellular TFV-diphosphate (TFV-DP) in cells from the female reproductive
tract (FRT) and whether sex hormones influence the presence of TFV-DP in these cells. Following incubation with TFV,
isolated epithelial cells, fibroblasts, CD4+ T cells and CD14+ cells from the FRT as well as blood CD4+ T cells and monocyte-
derived macrophages convert TFV to TFV-DP. Unexpectedly, we found that TFV-DP concentrations (fmol/million cells) vary
significantly with the cell type analyzed and the site within the FRT. Epithelial cells had 5-fold higher TFV-DP concentrations
than fibroblasts; endometrial epithelial cells had higher TFV-DP concentrations than cells from the ectocervix. Epithelial cells
had 125-fold higher TFV-DP concentrations than FRT CD4+ T cells, which were comparable to that measured in peripheral
blood CD4+ T cells. These findings suggest the existence of a TFV-DP gradient in the FRT where epithelial cells . fibroblasts
. CD4+ T cells and macrophages. In other studies, estradiol increased TFV-DP concentrations in endometrial and
endocervical/ectocervical epithelial cells, but had no effect on fibroblasts or CD4+ T cells from FRT tissues. In contrast,
progesterone alone and in combination with estradiol decreased TFV-DP concentrations in FRT CD4+ T cells. Our results
suggest that epithelial cells and fibroblasts are a repository of TFV-DP that is under hormonal control. These cells might act
either as a sink to decrease TFV availability to CD4+ T cells and macrophages in the FRT, or upon conversion of TFV-DP to
TFV increase TFV availability to HIV-target cells. In summary, these results indicate that intracellular TFV-DP varies with cell
type and location in the FRT and demonstrate that estradiol and/or progesterone regulate the intracellular concentrations
of TFV-DP in FRT epithelial cells and CD4+ T cells.
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Introduction
The Human Immunodeficiency Virus (HIV) global pandemic
has become one of the world’s most serious health challenges.
There were 35.3 million people living with HIV at the end of 2012
and about 2.3 million new infections during 2012 [1]. Worldwide,
the majority of new cases are spread by vaginal and anal sexual
intercourse, with a higher proportion of women infected via
heterosexual intercourse than men [2]. Younger age, sexual
violence, and co-infection with sexually transmitted infections
(STI) are among the risk factors that contribute to susceptibility to
HIV infection [3,4].
The female reproductive tract (FRT) is the primary mucosal site
of infection by STDs including HIV. Unique among mucosa sites,
the FRT is exposed to large fluxes in the levels of the sex hormones
estradiol (E2) and progesterone (P4) across the menstrual cycle,
and at concentrations higher than those observed elsewhere in the
body. Sex hormone modulation of innate and adaptive immune
protection led to the hypothesis of a ‘‘Window of Vulnerability’’
occurring during the later half of the menstrual cycle, when HIV
and other sexually transmitted pathogens are most likely to infect
women [5]. The FRT mucosa is composed of multiple cell types
including epithelial cells, fibroblasts and immune cells. Each plays
a central role in providing cellular, humoral, and innate immune
protection against bacterial and viral invasion as well as
physiological changes for reproductive success [6,7].
Recently, Pre-exposure Prophylaxis (PrEP) studies with anti-
retroviral drugs to prevent infection has provided hope to reduce
the dimensions of the HIV pandemic. For example, the
nucleoside-analog reverse transcriptase inhibitor (NRTI) tenofovir
demonstrated efficacy in in vitro studies, animal models and initial
clinical trials [8,9]. However, the use of oral TFV and TFV as a
vaginal gel in the Vaginal and Oral Interventions to Control the
Epidemic (VOICE) trial [10] failed to protect women against the
sexual acquisition of HIV [11,12].
Benefits of TFV include suppression of viral replication, a
favorable safety profile and a relatively long half-life [13]. After
entering the cell, TFV requires two phosphorylation steps to be
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activated into TFV-diphosphate (TFV-DP) [14]. TFV-DP can
compete for dATP during the HIV reverse transcriptase step and,
once incorporated into the nascent viral cDNA, causes chain
termination and thus inhibits viral replication. Since microbicides
are administered vaginally in gels or taken orally, it is important to
measure intracellular concentrations to be certain that TFV has
been absorbed in the mucosal tissue. TFV and TFV-DP
concentrations in human plasma, PBMCs, as well as genital and
colorectal tissues, have been measured for a number of HIV
prevention studies [11]. These studies have suggested a correlation
between drug concentration and efficacy. However, the intracel-
lular concentration of TFV-DP within individual cell types
(epithelial cells, fibroblasts and immune cells) at different sites
(endometrium (EM), endocervix (CX), ectocervix (ECX)) in the
FRT has not been studied. Additionally, the effects of sex
hormones and chemical contraceptives on TFV-DP concentra-
tions are poorly understood.
In this study, we evaluated the effects of E2 and/or P4 on TFV-
DP concentrations (fmol/million cells) in epithelial cells, fibroblasts
and immune cells (CD4+ T cells and macrophages) from sites in
the upper (EM, CX) and lower (ECX) FRT. The rationale for this
study was based on the recognition that to reach HIV-target cells
embedded in the stroma of the FRT, TFV taken orally must
permeate endothelial cells to enter the FRT stroma, or in the case
of vaginal deposition, move through and/or between epithelial
cells and fibroblasts to reach HIV-target cells (CD4+ T cells,
macrophages and dendritic cells) in the upper and lower FRT.
The goals of this study were to evaluate the ability of isolated cells
to activate TFV and to determine whether E2 and P4 regulate the
TFV-DP concentrations in epithelial cells, fibroblasts and immune
cells throughout the FRT.
Materials and Methods
Source of tissue and blood
Human FRT tissues were obtained immediately following
surgery from women who had undergone hysterectomies at
Dartmouth-Hitchcock Medical Center (Lebanon, NH). Tissues
from the EM, CX, and ECX were collected from hysterectomy
patients with benign conditions such as fibroids and prolapse (age
from 41 to 66). Tissue samples were distal from the sites of
pathology and were without pathological lesions as determined by
a pathologist. Blood donors were anonymous, no information
regarding age or hormonal status was available and only female
donors were used in this study. All human subject work was
carried out with the approval of the Dartmouth College
Institutional review Board. Approval to use tissues was previously
obtained from the Committee for the Protection of Human
Subjects (CPHS), and with written informed consent obtained
from the patient before surgery.
Tissue processing
Tissues were rinsed with 1x HBSS (Hanks balanced salt
solution) supplemented with phenol red, 100 U/ml penicillin,
100 mg/ml streptomycin (all Thermo Scientific Hyclone, Logan,
UT), and 0.35 mg/ml NaCO3 (Fisher Scientific, Pittsburgh, PA).
Tissues were then minced under sterile conditions into 1–2 mm
fragments and digested at 37uC for 1 hr using a mixture
containing (final concentrations): 0.05% collagenase type IV
(Sigma-Aldrich, St. Louis, MO) and 0.01% DNAse (Worthington
Biochemical, Lakewood, NJ) in 1xHBSS (Invitrogen Life Tech-
nologies, Grand Island, NY). Type IV collagenase was selected
based on preliminary studies to ensure non-cleavage of surface
markers (Rodriguez-Garcia et al, submitted). After digestion, cells
were dispersed through a 250-mm nylon mesh screen (Small Parts,
Miami Lakes, FL), washed, and resuspended in complete media
consisting of DMEM/F12 medium without phenol red, supple-
mented with 10 mM HEPES (both GIBCO, Life Technologies,
Grand Island, NY), 100 mg/ml primocin (InvivoGen, San Diego,
CA), 2 mM L-glutamine, 2.5% heat-inactivated defined fetal
Bovine Serum (FBS) (both from Thermo Scientific Hyclone) and
2.5% NuSerum (BD Biosciences, Bedford, MA). Epithelial cell
sheets were separated from stromal cells by filtration through a 20-
mm mesh filter (Small Parts). Epithelial cell sheets were retained on
the filter, while stromal cells passed through. Stromal cells were
then washed and counted and dead cells removed using the Dead
cell removal kit (Miltenyi Biotec, Auburn, CA) according to
manufacturer instructions to obtain a mixed cell suspension for
isolation of CD14+ cells, CD4+ T cells and fibroblasts.
Isolation and culture of FRT epithelial cells
Epithelial cell sheets were recovered by rinsing and backwashing
the filter with complete medium, centrifuged at 5006g for 5 min
and analyzed for cell number and viability. To establish a cell
culture system of polarized human FRT epithelial cells with both
apical and basolateral compartments, FRT epithelial cells were
cultured in Matrigel matrix (BD Biosciences) coated Falcon cell
culture inserts in 24-well companion culture plates (Fisher
Scientific). Apical and basolateral compartments contained 300
and 500 ml of complete medium, respectively, which was changed
every 2 days. Tight junction formation of epithelial cell
monolayers from EM and CX was assessed by periodically
measuring transepithelial resistance (TER) using an EVOM
electrode and Voltohmmeter (World Precision Instruments,
Sarasota, FL), as described previously [15–17]. To keep the
culture conditions similar, the same procedure was followed for
culturing squamous ECX epithelial cells, which do not polarize.
Isolation and culture of FRT CD14+ cells
Following removal of dead cells, CD14+ cells were isolated using
positive magnetic bead selection with the CD14 MicroBeads
(Miltenyi Biotec) according to the manufacturer’s instructions.
After two rounds of positive selection, purity of the CD14+ cell
population was higher than 90% (Rodriguez-Garcia et al,
submitted). Freshly isolated CD14+ cells were plated at a density
of 16105 cells per well in ultra-low attachment 96-well culture
plate (Corning, Corning, NY) in 0.2 ml of immune cell media
consisting of X-VIVO 15 Media (Lonza, Walkersville,MD)
supplemented with 10% charcoal stripped human AB serum
(Valley Biomedical, Winchester, VA) prior to treatment.
Isolation and culture of FRT CD4+ T cells and fibroblasts
Following removal of CD14+ cells, CD4+ T cells were isolated
from each cell suspension by negative magnetic bead selection
with the CD4+ T cell isolation kit (Miltenyi Biotec) following
instructions with minor modifications, as previously described
(Rodriguez-Garcia et al, submitted). Anti-fibroblast microbeads
(Miltenyi Biotec) were added in combination with the microbeads
supplied with the kit to ensure depletion of stromal fibroblasts
present in the mixed cell suspension. After two rounds of negative
selection, purity of the CD4+ T cell population was higher than
90% (Rodriguez-Garcia et al, submitted). Freshly isolated CD4+ T
cells from tissues were plated at a density of 16105 cells per well in
an ultra-low attachment 96-well culture plate (Corning, Corning,
NY) in 0.2 ml of immune cell media prior to treatment.
Fibroblasts were collected by positive selection using anti-
fibroblast microbeads as described above to purify CD4+ T cells.
TFV-DP in the Reproductive Tract
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Fibroblasts were cultured in T75 flasks (Falcon, Fisher Scientific,
Pittsburgh, PA) in complete medium as described above. The
medium was changed every 2 days for 4-6 days to remove non-
adherent cells. Purity was verified by intracellular staining of
vimentin and surface expression of CD90 and lack of CD45
[18,19]. Once fibroblasts reached confluence, they were trypsin-
ized with 0.05% trypsin-EDTA (GIBCO, Life Technologies) and
seeded into an ultra-low attachment 24-well culture plate
(Corning, Corning, NY) at a density of 16105 cells per well
(unless otherwise indicated) in 500 ml complete medium prior to
treatment, as described previously [20].
Preparation of blood Macrophages and CD4+ T cells
Peripheral blood mononuclear cells (PBMC) were isolated by
standard Ficoll density gradient centrifugation. To generate
monocyte-derived macrophages, as described previously [21],
CD14+ cells were isolated using positive magnetic bead selection
with the CD14 MicroBeads (Miltenyi Biotec) following instruc-
tions. Purity higher than 98% was obtained for CD14+ cell
populations after magnetic isolation by using Flow cytometry
analysis (data not shown). CD14+ cells were cultured in ultra-low
attachment T25 flasks (Corning, Corning, NY) with immune cell
media as described above. After 4 days, macrophages were plated
at a density of 16105 cells per well in ultra-low attachment 96-well
culture plate in 0.2 ml of immune cell media.
Blood CD4+ T cells were purified from PBMC using negative
magnetic bead selection with the CD4+ T cell isolation kit
(Miltenyi Biotec). Purity higher than 98% was obtained for CD4+
T cell populations after magnetic isolation by using Flow
cytometry analysis (data not shown). Freshly isolated CD4+ T
cells were plated at a density of 16105 cells per well (unless
otherwise indicated) in an ultra-low attachment 96-well culture
plate in 0.2 ml of immune cell media.
TFV preparation
TFV in powder form was obtained from AIDS Research and
Reference Reagent Program (NIH AIDS Reagent Program,
Division of AIDS, NIAID, NIH: Tenofovir, catalog number
10199). A stock concentration of TFV 10 mg/ml was prepared by
adding 1 ml of PBS to 10 mg of TFV powder. A final
concentration of 1 mg/ml of TFV was used unless otherwise
indicated.
Hormone preparation
17b-estradiol (Calbiochem, Gibbstown, NJ) and progesterone
(Calbiochem) was dissolved in 100% ethanol for an initial
concentration of 161023 M, evaporated to dryness and suspended
in media containing 10% charcoal dextran-stripped FBS or
immune cell complete media to a concentration of 161025 M.
Further dilutions were made to achieve final working concentra-
tion, and cells were treated with 561028 M E2 and/or 1610
27 M
P4. Both are standard hormone treatment concentrations used by
our laboratory and each is within the physiological range of
hormone concentration [22]. As a control, an equivalent amount
of ethanol without dissolved hormone was initially evaporated.
TFV and hormone treatment
Epithelial cells and fibroblasts in culture were switched to
complete media containing 10% of charcoal dextran-stripped FBS
prior to TFV and hormone treatment. After 24 hr, the media was
replaced and cells were treated with TFV and hormone for 24 hr.
Fresh isolated CD4+ T cells and CD14+ cells both from tissues and
blood were treated with TFV and hormone for 24 hr. Hormone
or ethanol control media was added to both the apical and
basolateral compartments (epithelial cells) or to individual wells for
all other cells. TFV was added to apical compartment only for
epithelial cell cultures, and to individual wells for all other cells.
After 24 hr treatment, cells were harvested and lysed in 300 ml of
70% methanol, and stored immediately at 280uC prior to TFV-
DP evaluation as previously described [23]. Intracellular TFV-DP
concentrations were measured by liquid chromatography with
tandem mass spectrometry (LC-MS/MS) and normalized for cell
count [23].
Statistics
Data analysis was performed using the GraphPad Prism 5.0
(GraphPad Software, San Diego, CA). A two sided P value,0.05
was considered statistically significant. Comparison of three or
more groups was performed applying One-way ANOVA with
Bonferroni post test. Comparison of normalized data was
performed applying column statistics – one sample t test, which
compares the mean of every column of data to the hypothetical
value (controls are by definition all equal to 100).
Results
TFV-DP is produced in multiple cell types
To obtain direct evidence on the extent to which cells are able
to activate TFV, we isolated blood CD4+ T cells and monocyte-
derived macrophages as well as endometrial fibroblasts and
epithelial cells and analyzed them for their ability to convert
TFV to TFV-DP. To optimize conditions for measuring TFV-DP,
increasing numbers of purified blood CD4+ T cells were incubated
with TFV (0.01–1.0 mg/ml) for 24 hr prior to measuring TFV-
DP concentrations by LC-MS/MS. As seen in Figure 1A, we
found that treating 50–400 K cells with TFV at 0.1 and 1 mg/ml
resulted in measurable TFV-DP. Lower concentrations of TFV
(0.01 mg/ml) at the cell numbers analyzed were insufficient to
measure TFV-DP. To optimize assay conditions, we analyzed the
data for blood CD4+ T cells on TFV-DP concentrations (fmol/
million cells) in Figure 1A. As shown in Figure 1B, we obtained
comparable TFV-DP over a range of cell concentrations when
adjusting for cell number (fmol/million cells). Based on these
analyses, we concluded that 100 K CD4+ T cells and 1 mg/ml
TFV were optimal for cell number and TFV concentration,
respectively. In other studies (not shown), we found that 100 K
cells and 1 mg/ml TFV was optimal for measuring TFV-DP in
blood monocyte-derived macrophages.
To determine if EM epithelial cells and fibroblasts metabolize
TFV to form TFV-DP, isolated cells were incubated with TFV for
24 hr prior to measuring TFV-DP. As seen in Figure 1C, we
found that TFV-DP increased with a higher dose of TFV in EM
epithelial cells (200 K). When we increased the number of EM
fibroblasts (50–200 K), we found higher concentrations of TFV-
DP with optimal 1 mg/ml of TFV (data not shown). When we
analyzed TFV-DP by fmol/million cells (Figure 1D), we
determined that 100 K were adequate for studies with FRT
fibroblasts. To the best of our knowledge, this is the first
demonstration that TFV-DP is formed in epithelial cells and
fibroblasts from the FRT. We also measured TFV-DP in CD4+ T
cells and CD14+ cells from FRT tissues and found that treating
100 K cells with TFV at 1 mg/ml resulted in measurable TFV-
DP (data not shown).
TFV-DP in the Reproductive Tract
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2. TFV-DP within FRT tissues vary with the individual cell
types analyzed
Following optimization of measuring TFV-DP in terms of cell
numbers for each cell type, we evaluated TFV-DP in isolated cells
(epithelial cells, fibroblasts, CD4+ T cells and CD14+ cells) from
FRT tissues (EM, CX, ECX) which have been treated with TFV
at 1 mg/ml for 24 hr and compared TFV-DP values to that seen
in CD4+ T cells and monocyte-derived macrophages from blood.
As seen in Figure 2, analysis of isolated cells from FRT tissues
showed a significant variation in TFV-DP for the different cell
types. TFV-DP in epithelial cells were 5-fold greater than in
fibroblasts, with mean TFV-DP values of 2.56106 fmol/million
cells versus 0.56106 fmol/million cells, respectively (p = 0.0006).
Interestingly, TFV-DP in epithelial cells were approximately 50-
fold and 125-fold greater than in FRT CD14+ cells and CD4+ T
cells, respectively (p = 0.003 and 0.0002). Additionally, TFV-DP in
FRT CD4+ T cells was comparable to that measured in blood
CD4+ T cells. Our studies suggest that a cellular gradient in which
individual FRT cell types are exposed to TFV results in TFV-DP
concentrations that vary with cell type with epithelial cells .
fibroblasts . CD14+ cells and CD4+ T cells.
3. TFV-DP in epithelial cells vary with the FRT tissue
analyzed
To determine the variation of TFV-DP in individual cells from
different FRT locations, purified epithelial cells from the upper
and lower FRT were incubated with TFV at 1 mg/ml for 24 hr.
As seen in Figure 3, TFV-DP in EM epithelial cells (46106 fmol/
million cells) were 1.9-fold (2.16106 fmol/million cells) and 2.7-
fold (1.56106 fmol/million cells) greater than in epithelial cells
from CX or ECX, respectively (p = 0.04 and 0.05). In contrast,
TFV-DP concentrations in fibroblasts from EM, CX and ECX
were comparable in our preliminary results and did not vary with
the site analyzed (data not shown).
4. Effect of estradiol and/or progesterone on TFV-DP in
FRT epithelial cells
To determine whether E2 and P4 alone or in combination have
an effect on TFV-DP in primary FRT epithelial cells, purified cells
were incubated with TFV (1 mg/ml) and E2 (5610
28 M), P4
(161027 M) or a combination of E2 and P4 for 24 hr. As shown
with epithelial cells from 4-5 patients (Figure 4A), E2 treatment
significantly increased TFV-DP in polarized EM epithelial cells. In
Figure 1. Blood CD4+ T cells and endometrial epithelial cells
and fibroblasts metabolize TFV to TFV-DP. TFV-DP levels were
measured by LC-MS/MS in increasing numbers of purified blood CD4+ T
cells (A and B) and EM epithelial cells (C) and fibroblasts (D) treated with
indicated dose of TFV for 24 hr. Bars represent mean and SEM from
triplicate cultures. Values are expressed as fmol per ml in (A) and fmol/
million cells in (B, C and D).
doi:10.1371/journal.pone.0100863.g001
Figure 2. Comparison of TFV-DP levels in epithelial cells,
fibroblasts, CD14+ cells and CD4+ T cells from FRT tissues. TFV-
DP levels were measured by LC-MS/MS in purified cultures of epithelial
cells (n = 14), fibroblasts (n = 6), CD14+ cells (n = 4) and CD4+ T cells
(n = 8) from FRT tissues as well as monocyte-derived macrophages
(n = 2) and CD4+ T cells (n = 4) from blood treated with TFV (1 mg/ml)
for 24 hr. Each circle represents FRT cells from an individual patient or
blood cells from different female donors. Values are expressed as fmol/
million cells. The mean and SEM are shown. *, p,0.05, **, p,0.01,
***, p,0.001.
doi:10.1371/journal.pone.0100863.g002
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contrast, P4 had no effect. Interestingly, however, when E2 was
added along with P4, no stimulatory effect was observed.
Similarly, we found that E2 treatment of CX and ECX epithelial
cells grown on cell inserts increased TFV-DP from 6 patients
(Figure 4B). In these studies, data from CX and ECX were
combined owing to the limited numbers of tissues available for this
study. Also shown in Figure 4B are studies carried out with P4.
5. Effect of estradiol and/or progesterone on TFV-DP in
CD4+ T cells from the FRT and blood
To determine whether E2 and/or P4 influence TFV-DP
concentrations in FRT and blood CD4+ T cells, purified CD4+
T cells were isolated by magnetic bead selection and incubated
with TFV (1 mg/ml) using the same hormone protocol described
above for epithelial cells and fibroblasts. As shown with FRT
CD4+ T cells from a representative patient (Figure 5A) or 4–6
patients (Figure 5B), P4 in combination with E2 treatment
significantly decreased TFV-DP concentrations. Moreover, P4
alone significantly decreased TFV-DP concentrations in 3/4
patients whereas E2 had no effect in 4/4 experiments. In contrast,
as seen in Figure 5C, TFV-DP concentrations in blood CD4+ T
cells from female donors were unaffected by E2 and/or P4.
6. Effect of estradiol and/or progesterone on TFV-DP in
FRT fibroblasts
To determine whether E2 and/or P4 has an effect on TFV-DP
in primary FRT fibroblasts, isolated fibroblasts were treated with
TFV (1 mg/ml) and sex hormones. We found that E2 and P4
either alone or in combination had no effect on TFV-DP in FRT
fibroblasts. Interestingly, P4 either alone or in combination with
E2 treatment decreased TFV-DP 20–40% in fibroblasts from CX
and ECX in 3 out of 5 experiments (data not shown). Further
studies are needed to determine the significance of these
preliminary results.
Discussion
In the present study we demonstrate that immune and non-
immune cells from the human FRT take up TFV and activate it to
TFV-DP, the active form that inhibits reverse transcriptase to
block HIV infection of target cells. To the best of our knowledge
this study is the first to determine: i) the concentrations of TFV-DP
in different cell types at different locations within the FRT and ii)
the effect of sex hormones on these concentrations. We found that
TFV-DP concentrations vary significantly with the cell type
analyzed and the site within the FRT, suggesting the presence of a
gradient of intracellular TFV-DP in which epithelial cells .
fibroblasts . CD4+ T cells and CD14+ cells. The data presented
also shows that E2 and P4 are directly involved in regulating
intracellular TFV-DP concentrations in epithelial cells and CD4+
T cells, one of the main target cells of HIV.
A key observation from this study was that FRT epithelial cells
and fibroblasts are able to phosphorylate TFV and generate
intracellular TFV-DP more efficiently than CD4+ T cells and
CD14+ cells. TFV-DP concentrations achieved in these non-target
cells were considerably greater than in HIV target cells. As
assessed per million cells, TFV-DP in FRT epithelial cells were
approximately 53-fold and 125-fold greater than in FRT CD14+
cells and CD4+ T cells, respectively. TFV-DP in FRT fibroblasts
were approximately 10-fold and 25-fold greater than in FRT
CD14+ cells and CD4+ T cells, respectively. Interestingly,
Figure 3. TFV-DP levels in epithelial cells FRT endometrium,
endocervix and ectocervix tissue. TFV-DP levels were measured by
LC-MS/MS in purified cultures of EM (n = 4), CX (n = 7) and ECX (n = 3)
epithelial cells treated with TFV (1 mg/ml) for 24 hr. Each circle
represents an individual patient. Values are expressed as fmol/million
cells. The mean and SEM are shown. *, p,0.05.
doi:10.1371/journal.pone.0100863.g003
Figure 4. Effect of estradiol and/or progesterone on TFV-DP levels in epithelial cells from endometrium, endocervix and ectocervix.
TFV-DP levels were measured by LC-MS/MS in polarized cultures of FRT epithelial cells treated with TFV (1 mg/ml) and estradiol (561028 M),
progesterone (161027 M), either alone or the combination for 24 hr. Data were normalized to % of control values from (A) EM epithelial cells (n = 4–
5) and (B) CX/ECX epithelial cells (n = 3–8). Dashed line indicates an assigned value of 100. Each circle represents a different patient. Dark circles
indicate (A) EM epithelial cells and (B) CX epithelial cells. Open circles indicate ECX epithelial cells. The mean and SEM are shown. *, p,0.05.
doi:10.1371/journal.pone.0100863.g004
TFV-DP in the Reproductive Tract
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concentrations of TFV-DP in FRT CD4+ T cells were comparable
to that measured in blood CD4+ T cells. The FRT mucosa is
composed of multiple cell types and the predominant cell types are
epithelial cells and fibroblasts [24]. Our studies suggest that the
predominance of these epithelial cells with their high intracellular
concentrations of TFV-DP may lead to an over estimation of
TFV-DP concentrations ascribed to HIV target cells as reported
tissue biopsy or cytobrush samples [12].
The TFV-DP concentration measured in this study describe a
potential gradient that occurs both with the cell type (epithelial
cells . fibroblasts . CD14+ cells and CD4+ T cells) and FRT
location (epithelial cells, EM . CX or ECX). The relatively low
TFV-DP in CD4+ T cells and macrophages suggest that, because
of sequestration of TFV by epithelial cells and fibroblasts accounts
for 50-70% of non-myometrial cells in the FRT, some ART drugs
may not achieve sufficient concentrations to effectively suppress
local replication of HIV in HIV target cells [25]. Based on
preliminary studies from our laboratory (Bodwell et al, Unpub-
lished observation), we know that epithelial and stromal fibroblasts
possess the enzymatic machinery necessary to both activate TFV
and inactivate TFV-DP. Once inactivated, TFV can readily move
out of these cells to be available for uptake and metabolic
activation by HIV target cells [14]. Our results in the present study
suggest that epithelial cells and fibroblasts are a repository of TFV-
DP. At the heart of this hypothesis is the recognition that epithelial
cells and fibroblasts might act either as a sink to decrease TFV
availability to CD4+ T cells and macrophages in the FRT, or on
conversion of TFV-DP to TFV, increase TFV available to HIV
target cells.
Given the high intracellular active tenofovir levels achieved in
these studies, it is possible that FRT epithelial cells may be prone
to toxic side effects. Tenofovir as a DNA chain terminator NRTI
drug causes mitochondrial dysfunction in renal proximal tubules
[26–28]. MTN-001 findings showed that TFV-PP levels in biopsy
vagina tissues are ,130 times higher with vaginal gel TFV
compared to that measured in the vagina after oral drug
administration [12]. The data presented here implies that active
drug levels, specifically in genital epithelial cells, could reach
substantially higher peaks in situ.
Recognizing that sex hormones affect most if not all metabolic
events in the FRT [29], we asked whether E2 and/or P4 influence
the intracellular concentrations of TFV-DP within immune and
non-immune cells in the FRT. Our findings indicate that the
effects of sex hormones on TFV-DP are quite divergent and
dependent on the cell type. Thus while E2 alone in culture
increased TFV-DP in EM and CX/ECX epithelial cells, P4 in
combination with E2 decreased TFV-DP in CD4
+ T cells from
FRT tissues. An unexpected finding in our study was that whereas
both epithelial cells and fibroblasts contain E2 and P4 receptors
and are responsive to sex hormones [29], hormone treatment of
fibroblasts failed to alter TDV-DP in fibroblasts. Just why these
cells differ in their responsiveness to E2 remains unclear. In
previous studies we have seen differential responses between
fibroblasts from different sites in the FRT. For example, whereas
E2 stimulates hepatocyte growth factor (HGF) secretion by EM
fibroblasts, it had no effect on CX and ECX fibroblast secretion of
HGF [30]. In response to E2, EM epithelial cell secretion of HBD2
and Elafin increased, but was inhibited when vaginal epithelial
cells were treated with E2 [31]. Our finding that fibroblasts are
non-responsive to hormones with respect to TFV-DP concentra-
tions suggests the possibility that the two subtypes of estrogen
receptor (ER), ERa to ERb in fibroblasts might be different from
that in epithelial cells. Since E2 exerts its molecular actions by
interactions with ERa and ERb, which are now recognized as
consisting of multiple isoforms [32], further studies are needed to
identify the unique mechanisms involved in TFV-DP availability.
We previously hypothesized that women are most susceptible to
HIV infection when E2 and P4 levels are highest during ovulation
and the secretory phase of the menstrual cycle [5]. Protection in
Figure 5. Effect of estradiol and/or progesterone on TFV-DP
levels in CD4+ T cells from FRT and blood. TFV-DP levels were
measured by LC-MS/MS in purified FRT and blood CD4+ T cells treated
with TFV (1 mg/ml) and either estradiol (561028 M), progesterone
(161027 M), or the combination for 24 hr. Values are expressed as
fmol/million cells in (A) EM CD4+ T cells (patient number 6319). The Bars
represent mean and SEM from triplicate cultures. Data were normalized
to % of control values from (B) FRT CD4+ T cells (n = 4–6) and (C) blood
CD4+ T cells (n = 3–4). Dashed line indicates an assigned value of 100.
Each circle or triangle represents a different patient or blood donor.
Dark circles indicate (B) EM CD4+ T cells or (C) blood CD4+ T cells. Open
circles indicate CX CD4+ T cells and triangles indicate ECX CD4+ T cells.
The mean and SEM are shown. *, p,0.05, **, p,0.01, ***, p,0.001.
doi:10.1371/journal.pone.0100863.g005
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the FRT is shared between the innate and adaptive immune
systems and both are under hormonal control [6,7]. Given this
immune regulation by sex hormones, we asked whether E2 and P4
influence the intracellular concentrations of TFV-DP in cells from
the FRT. Our findings that E2 increases TFV-DP in epithelial cells
from the EM and CX/ECX suggest that when E2 levels are
elevated, intracellular TFV-DP in epithelial cells will be high. If so,
then increased uptake and activation to TFV-DP by epithelial cells
might lower TFV available for uptake by HIV target cells.
Conversely, when E2 levels are low, as during the proliferative
phase of the menstrual cycle, epithelial cell conversion of TFV-DP
back to TFV could contribute to enhanced protection, measured
as a greater availability of TFV for HIV target cells. Further
studies are needed to determine whether epithelial cells provide a
meaningful source of TFV for HIV target cells or if hormonal
changes compromise microbicide mediated protection against
HIV in the FRT.
Previously, we demonstrated that E2 enhances nucleotidase
(NT) expression and biological activity in epithelial cells and
fibroblasts from upper and lower FRT [20]. E2, but not P4 either
alone or in combination, increased gene expression of Cytosolic
59-nucleotidase after 2 or 4 hr in EM epithelial cells but not
epithelial cells or fibroblasts from other sites. However, in studies
using a modified 59-NT biological assay for nucleotidases, E2
increased NT activity in epithelial cells and fibroblasts from the
EM, CX and ECX at 24 and 48 hr. Nucleotidases have
phosphatase activity and are involved in the catabolism of
nucleotides through dephosphorylation of nucleotide terminal
phosphates with a preference for nucleotide monophosphates [33]
and have been implicated in TFV metabolism. Our findings of
increased intracellular TFV-DP in epithelial cells in response to E2
are opposite to our earlier findings of enhanced NT activity, since
enhanced NT activity would be expected to decrease TFV-DP,
not enhance them as found. The present studies indicate that
either NT enzymes are not key players in the catabolism of TFV-
DP or that E2 enhances formation through the stimulation of
kinase activity to offset changes in increased phosphatase activity.
Future studies are needed that focus on the dynamic balance of the
enzymes (kinases) necessary for formation of activated microbicide
TFV-DP and those required for TFV-DP degradation (nucleotid-
ases and phosphatases) in HIV-target cells.
Beyond the E2 effects on TFV-DP, we found that P4 in
combination with E2 decreases TFV-DP in CD4
+ T cells from the
FRT. In studies to measure TFV and TFV-DP concentrations in
blood and blood PBMC, Coleman et al. found that the use of
hormonal contraception (oral and injectable) was associated with
decreased serum and intracellular PBMC TFV concentrations
[34]. Since as many as 70% of women in TFV PrEP trials used
some form of chemical contraception, our findings that sex
hormones alter TFV-DP in immune and non-immune cells from
the FRT, when considered along with those of Coleman et al.,
provide compelling evidence that studies are needed to determine
the extent to which intracellular TFV-DP within CD4+ T cells and
macrophages in the FRT change with stage of the menstrual cycle
and hormonal contraceptive use and whether these changes
enhance or reduce susceptibility to HIV infection.
In conclusion, these studies demonstrate measurable TFV-DP
in epithelial cells, fibroblasts and immune cells from the upper and
lower FRT. Intracellular concentrations vary with the cell type
and location within the FRT. In addition, these results indicate
that sex hormones regulate the production of TFV-DP in
epithelial cells, suggesting that they may alter both TFV
availability to HIV target cells and protection against HIV in
the FRT. Future studies are needed to understand the mechanisms
involved in the modulation of microbicide concentrations by sex
hormones and chemical contraceptives in FRT tissues and how
these relate to PrEP trial outcomes in order to more fully define
the complex interactions of the endocrine system and its influence
on microbicide efficacy and protection against HIV.
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